Gordian Biotechnology is introducing a method of screening hundreds of gene therapies simultaneously in an individual animal model - its co-founders explain
The CEO of Jasper Therapeutics on c-KIT inhibition
Visiting Adaptimmune on its investor day and ahead of this year's FDA decision for the TCR cell therapy afami-cel in synovial sarcoma
Ultragenyx's Emil Kakkis on this week's Angelman syndrome data, rare disease treatment modalities, and more
The CEO of Madrigal on the launch of Rezdiffra for NASH liver disease
AACR24: Having entered the clinic last night, Nested's CEO discusses the preclinical profile of a brain-penetrant, pan-RAF/MEK molecular glue
AACR24: EpicentRx’s phase 2a using TGF-β trap to overcome checkpoint resistance
Daphne Zohar on becoming the CEO of Seaport Therapeutics and today's $100M series A
Syncromune's AACR late-breaker of phase 1 data for the SYNC-T immunotherapy drug-device combo in mCRPC
Carisma Therapeutics' CEO on refocusing its pipeline this week and what the company has learned in the clinic
Sutro Biopharma's CEO on ADCs, non-cell protein synthesis, and more
San Diego's Alterome Therapeutics raised a $132M Series B today for its precision oncology platform
Spun out of Paragon, Oruka Therapeutics raised $275M today as part of a reverse merger to tackle skin conditions in the I&I space
Verve Therapeutics' CEO on today's gene editing clinical trial pause
Kyverna's CEO on B-cell depletion and CD19 CAR-T for autoimmune conditions
Nkarta CEO Paul Hastings on NK based cell therapies for autoimmune conditions
Checking in with Geron's CEO after imetelstat's recent ODAC meeting
Mirador Therapeutics launched with a $400M+ fundraising round today for precision medicine in the I&I space
MeiraGTx's CEO on the gene therapy field and upcoming data her company will have over the coming quarters
Taking a deep dive into last week's T-cell engager data with the CEO of Janux Therapeutics
.png){kind=logo}
